Alnylam presents positive phase 3 results from illuminate-a study of lumasiran

Alnylam presents positive phase 3 results from illuminate-a study of lumasiran, an investigational rnai therapeutic for treatment of primary hyperoxaluria type 1.alnylam-lumasiran met primary efficacy endpoint of 24-hour urinary oxalate reduction from month 3 to 6 relative to placebo,all tested secondary endpoints.
ALNY Ratings Summary
ALNY Quant Ranking